Drug
Seliciclib
Seliciclib is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
2
67%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(2)
Detailed Status
Recruiting1
Terminated1
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 22 (66.7%)
Trials by Status
recruiting133%
terminated133%
withdrawn133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
NCT03774446
terminatedphase_2
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
NCT00372073
withdrawnphase_1
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
NCT01333423
Clinical Trials (3)
Showing 3 of 3 trials
NCT03774446Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
NCT00372073Phase 2
Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer
NCT01333423Phase 1
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3